Subcutaneous bortezomib for multiple myeloma treatment: patients&amp;rsquo; benefits

Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies. HRQoL/functioning and symptoms of patients with relapsed/refractory MM (RRMM) receiving second- or third-line lenalidomide or bortezomib treatment were measured in a prospective European multicentre, observational study at different time points. At baseline, patients in the lenalidomide cohort were frailer than in the bortezomib cohort with more rapid disease progression at study entry (more patients with Eastern Cooperative Oncology Group performance status >2, shorter time from diagnosis, more chronic heart failure, higher serum creatinine levels, more patients with dialysis required). About 40% of the patients receiving lenalidomide discontinued the study in <6 months while 55% in the bortezomib cohort discontinued. No substantial HRQoL deterioration was observed for the first 6 months in patients with RRMM receiving one or the other treatment. For patients still on treatment at study completion (month 6), only the European Organization for Research and Treatment of Cancer Quality-of-Life Core domains of Diarrhoea and Global Health Status/QoL had worsened in the lenalidomide and bortezomib cohorts, respectively. A clinically meaningful deterioration in HRQoL was more often observed for patients who discontinued the study prior to 6 months in the bortezomib cohort than in the lenalidomide cohort.

show abstract

“…28 This prevented us from drawing meaningful conclusions with regard to QoL between subcutaneously and intravenously administered bortezomib.…”

Section: Discussionmentioning

confidence: 99%

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

Leleu

Kyriakou

Broek

et al. 2017

Blood Cancer Journal

View full text Add to dashboard Cite

show abstract

“…SC bortezomib greatly ameliorated patient quality of life, as it reduced peripheral neuropathy (Petrucci et al , ). SC bortezomib is easy to administer and is time saving for patients and professionals in the hospital.…”

Section: Characteristics Of Sc Bortezomib‐treated Patientsmentioning

confidence: 99%

Intravenous (IV) bortezomib infusion after non‐response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?

et al. 2016

View full text Add to dashboard Cite

“…[24] Therefore, alternative less toxic regimens are being sought, such as changing from twice weekly to once weekly [22,25–27] or from the traditional intravenous administration to subcutaneous injection. [28,29] So far, the studies suggest that the efficacy of the bortezomib once weekly regimen was relatively good and with low toxicity.…”

Section: Introductionmentioning

confidence: 99%

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China

Yao

Zhou

et al. 2019

Medicine

View full text Add to dashboard Cite

The study aims to examine the treatment effect and adverse reactions of patients with newly diagnosed MM receiving different bortezomib-based regimens.This was a retrospective study of patients with newly diagnosed MM and who were treated with bortezomib-based combined chemotherapy at the Department of Hematology of the 2 affiliated hospitals of Wenzhou Medical University between July 2009 and May 2016. Cox proportion hazard multivariate analyses were carried out to assess the differences in treatment effect and adverse events between standard (1.3 mg/m2 on days 1, 4, 8, 11) and weekly (1.6 mg/m2 on days 1, 8, 15) cohorts, as well as the differences between intravenous injection and subcutaneous injection therapy. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan–Meier method and the log-rank test.Among the 117 patients, 78 patients were treated with bortezomib standard therapy and 39 patients were treated with bortezomib weekly therapy (all with intravenous injection). In all patients, the treatment strategy was not independently associated with PFS or OS. The patients in the weekly therapy group had less thrombocytopenia events than those in the standard therapy group. The subcutaneous route had similar treatment effect as the intravenous route, but the incidence of peripheral neuropathy was lower.The once-weekly bortezomib regimen was similar in effectiveness to standard therapy in treating patients with newly diagnosed MM, but the incidence of thrombocytopenia was lower with the weekly regimen compared with the standard regimen.

show abstract

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits

Cited by 14 publications

References 46 publications

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment

Intravenous (IV) bortezomib infusion after non‐response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China

Contact Info

Product

Resources

About